以肠道菌群为靶点治疗原发性胆汁性胆管炎的临床应用  

Treatment of primary biliary cholangitis by targeting intestinal flora

作　　者：马铭涵 刘彦琦[1] MA Minghan;LIU Yanqi(Department of Gastroenterology,The Affiliated Hospital of Inner Mongolia Medical University,Huhehot 010050,China)

机构地区：[1]内蒙古医科大学附属医院消化科,呼和浩特010050

出　　处：《临床肝胆病杂志》2023年第1期188-192,共5页Journal of Clinical Hepatology

基　　金：内蒙古自治区卫生健康科技计划项目(202201282);内蒙古自治区自然科学基金项目(2022LHMS08019)。

摘　　要：原发性胆汁性胆管炎(PBC)是一种以胆管上皮细胞为特征性靶标的进行性胆汁淤积性肝病。“疾病肠治”是近年的研究热点。未来或可通过益生菌改善肠道菌群丰度及分布,重塑肠道微环境,进而干预PBC疾病进展。本文从肠道菌群角度及益生菌的临床应用方面进行综述,为PBC寻找新的治疗策略提供思路。Primary biliary cholangitis(PBC)is a progressive cholestatic liver disease targeting biliary epithelial cells,and the concept of“treating diseases by intervening with the gut”has become a research hotspot in recent years.In the future,probiotics may be used to improve the abundance and distribution of intestinal flora,reshape the intestinal microenvironment,and intervene against the progression of PBC.This article reviews the gut microbiota and the clinical application of probiotics,so as to provide ideas for finding new treatment strategies for PBC.

关 键 词：肝硬化 胆汁性 胃肠道微生物组 治疗学 

分 类 号：R575.7[医药卫生—消化系统]